Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a…
Month: April 2022
X4 Pharmaceuticals to Present at April Investor Conferences
BOSTON, April 04, 2022 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the…
Genocea Biosciences to Host Investor Webinar
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) — Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical…
COMPASS Pathways to participate in Needham Healthcare conference
LONDON, April 04, 2022 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health…
Selecta Biosciences to Participate at the 21st Annual Needham Virtual Healthcare Conference
WATERTOWN, Mass., April 04, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology…
Nautilus Biotechnology to Present at EuPA and AACR Meetings
• Co-founder and Chief Scientist Parag Mallick, Ph.D., to present lecture at Annual Congress of…
Humacyte Announces Date of Annual Shareholder Meeting
DURHAM, N.C., April 04, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology…
Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
WORCESTER, Mass., April 04, 2022 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a…
Digipath to Provide Product Testing for Redwood Cultivation Products, Including Mike Tyson’s New Ear Shaped Gummies, ‘Mike Bites’
LAS VEGAS, NV, April 04, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Digipath, Inc. (OTCQB:…
Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting
– Webcast will feature Professor Charles Swanton, TRACERx Chief Investigator and Achilles co-founder – –…
Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development
ALG-097558 demonstrates nanomolar potent antiviral activity and is up to 20-fold more active than nirmatrelvir…
CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis
NEWARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical…
Lexicon Welcomes New Guidelines for the Management of Heart Failure
Guidelines issued jointly by the American Heart Association, American College of Cardiology and Heart Failure Society…
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting
NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from…
Arch Therapeutics’ AC5® Advanced Wound System to be Presented at 2022 Symposium on Advanced Wound Care (SAWC) Spring
Additional case studies and key opinion leader discussion continues to support the broad potential of…
Innovation1 Biotech (IVBT) Completes Name and Ticker Symbol Change from Gridiron BioNutrients (GMVP)
NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) — Innovation1 Biotech Inc. (OTCQB: IVBT) (“Innovation1” or…
Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency
– Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) levels observed in all three…
Applied Therapeutics to Present at the 43rd Annual Meeting of the Society for Inherited Metabolic Disorders
NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage…
Wave Life Sciences Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study Driven by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004
Reductions in poly(GP), a key disease biomarker indicating target engagement, observed across all treatment groups…
AnPac Bio Filed Request for a Hearing Regarding Continued Listing on NASDAQ, The Hearing was Granted and scheduled for Late April
PHILADELPHIA, April 04, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the…